基礎研究

  1. ホーム
  2. 研究
  3. 基礎研究
  4. 白血病遺伝学および血小板グループ
白血病遺伝学および血小板グループ
造血幹細胞移植・免疫療法グループ
リンパ系腫瘍グループ

白血病遺伝学および血小板グループ Leukemia Genetics and Platelets Group

グループリーダー 小野澤真弘
松川敏大
メンバー 宮下直樹、木村弘幸、吉田匠汰、長井惇、藤井文彰
OB 宮下直洋、橋口淳一、日高大輔、横山　翔大、髙橋承吾

白血病に限らず、悪性腫瘍は遺伝子の異常により引き起こされます。白血病で繰り返し起きる遺伝子異常を確認することは、予後予測に重要であるばかりでなく、治療選択にも直結する時代が始まっています。私が初めて米国血液学会に参加した2004年、世界ではすでにFLT3-ITD, NPM1, CEBPA変異の有無で正常核型のAMLの予後が層別化できることが発表されていました。それから20年たった現在の日本において、未だにこれらの遺伝子変異全てを保険診療で調べることはできません。当グループでは北日本血液研究会（NJHSG）の自主臨床研究「急性白血病における遺伝子変異と治療反応性・白血病発症機序の解明」、通称：北海道白血病ネット(Hokkaido Leukemia Net)を主催しています。参加施設の急性白血病検体を収集し、予後に関わる変異解析を行い主治医に返却しています。のべ1600例を超える白血病サンプルを所有し、新規の登録は年間270例を超えています。これは欧米の大規模コホートに匹敵する症例規模であり、毎年予後追跡データを更新しています。この活動を通じて、臨床に貢献すると共に、新たな知見を生み出していきます。

白血病に関するテーマ

  1. 急性骨髄性白血病における遺伝子変異の発生機序
  2. 急性骨髄性白血病における分子標的薬耐性機序の解明とその克服
  3. MRD検出検査の開発と検証

また、患者様との巡り会いから、導かれるように血小板研究も行い成果を上げつつあります。

血小板に関するテーマ

  1. 巨大血小板を伴う先天性血小板減少をきたす新規インテグリン変異とその機能解析
  2. アナグレリドによる血小板減少効果の解析
  3. 家族性血小板増多症に関わる変異解析

当グループでは目の前にある臨床上の疑問に科学的に答えを出すことを目標に、様々なテーマに取り組んでいます。テーマごとに共同研究の輪を広げ、限られた時間、限られた資金で効率的な研究を進めます。大学院生には臨床論文１本、基礎論文１本を目指してもらっています。やる気のある若手の参加をお待ちしています。

（文責：小野澤）

Publication list (since 2014)

  1. Relative impact of THPO mutation causing hereditary thrombocythemia.
    Kimura H, Onozawa M, Matsukawa T, Goto H, Kondo T, Teshima T.
    Exp Hematol. 2024 Mar 26:104208.
  2. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators.
    J Clin Oncol. 2024 Mar 12:JCO2302474.
  3. Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Miyashita N, Onozawa M, Matsukawa T, Mori A, Hidaka D, Minauchi K, Shigematsu A, Hashiguchi J, Igarashi T, Kakinoki Y, Tsutsumi Y, Ibata M, Wakasa K, Fujimoto K, Ishihara T, Sakai H, Iyama S, Oyake T, Kondo T, Teshima T.
    Br J Haematol. 2024 Apr;204(4):1549-1553.
  4. Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family.
    Kimura H, Onozawa M, Hashiguchi J, Hidaka D, Kanaya M, Matsukawa T, Okada H, Kondo T, Matsuno Y, Teshima T.
    Ann Hematol. 2024 Jan;103(1):89-96.
  5. Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans.
    Kimura H, Onozawa M, Teshima T.
    Platelets. 2023 Dec;34(1):2276697.
  6. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
    Chang YS, Gills JJ, Kawabata S, Onozawa M, Della Gatta G, Ferrando AA, Aplan PD, Dennis PA.
    Int J Oncol. 2023 Nov;63(5):128.
  7. Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
    Vaswani PPM, Onozawa M, Hasegawa Y, Ohigashi H, Ara T, Matsukawa T, Yasumoto A, Shiratori S, Goto H, Nakagawa M, Kahata K, Endo T, Hashimoto D, Teshima T.
    Bone Marrow Transplant. 2023 Dec;58(12):1397-1399.
  8. Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review.
    Kosaka N, Uchiyama T, Onozawa M, Nagai J, Koya J, Ishizaka S, Nagai T, Ikebe Y, Kato K, Tanei ZI, Sakakibara-Konishi J, Hasegawa Y, Ohigashi H, Goto H, Hashimoto D, Ujiie H, Hirano S, Konno S, Anzai T, Taniguchi K, Tanaka S, Teshima T.
    Intern Med. 2024 Apr 16. doi: 10.2169/internalmedicine.3505-24.
  9. Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
    Kimura H, Onozawa M, Yoshida S, Miyashita N, Yokoyama S, Matsukawa T, Hirabayashi S, Goto H, Endo T, Oguri S, Fujisawa S, Mori A, Kondo T, Hidaka D, Okada K, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Hashiguchi J, Nagashima T, Ibata M, Wakasa K, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Teshima T.
    Ann Hematol. 2023 Nov;102(11):3103-3113.
  10. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Miyajima T, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Goto H, Sugita J, Fujisawa S, Hidaka D, Ogasawara R, Mori A, Matsuoka S, Shigematsu A, Wakasa K, Kasahara I, Saga T, Hashiguchi J, Takeda Y, Ibata M, Yutaka T, Fujimoto K, Kondo T, Teshima T.
    Eur J Haematol. 2023 Oct;111(4):620-627.
  11. Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
    Kikuchi R, Onozawa M, Nagai J, Okada S, Hasegawa Y, Ohigashi H, Mitamura S, Maeda T, Takakuwa E, Fujieda Y, Goto H, Hashimoto D, Matsuno Y, Teshima T.
    Intern Med. 2024 Feb 15;63(4):541-545.
  12. Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
    Yokoyama S, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, Matsukawa T, Goto H, Fujisawa S, Miki K, Hidaka D, Hashiguchi J, Wakasa K, Ibata M, Takeda Y, Shigematsu A, Fujimoto K, Tsutsumi Y, Mori A, Ishihara T, Kakinoki Y, Kondo T, Hashimoto D, Teshima T.
    Br J Haematol. 2023 Jun;201(6):1144-1152.
  13. Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.
    Tada M, Kachi S, Onozawa M, Fujieda Y, Yoshida S, Oki Y, Kamada K, Nagai J, Okada S, Kikuchi R, Hisada R, Hasegawa Y, Ohigashi H, Goto H, Hashimoto D, Nakazato S, Matsuno Y, Teshima T, Atsumi T.
    Intern Med. 2023 Nov 1;62(21):3231-3235.
  14. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733-z.
  15. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Hirabayashi S, Fujisawa S, Mori A, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Ibata M, Wakasa K, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Kondo T, Teshima T.
    Int J Hematol. 2023 Jul;118(1):36-46.
  16. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Yoshida S, Onozawa M, Miyashita N, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Hirabayashi S, Mori A, Hidaka D, Minauchi K, Shigematsu A, Hashiguchi J, Igarashi T, Kakinoki Y, Tsutsumi Y, Ibata M, Kobayashi H, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Ota S, Kondo T, Teshima T.
    Int J Hematol. 2023 Apr;117(4):544-552.
  17. Prognostic factors in patients in the terminal phase of haematological malignancies who are receiving home medical care.
    Miyashita N, Ohashi K, Fujita M, Hosoda T, Kawasaki Y, Takimoto M, Onozawa M.
    Br J Haematol. 2023 Apr;201(2):290-301.
  18. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
    Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ.
    Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10.
  19. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
    Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T.
    Sci Rep. 2022 May 25;12(1):8885.
  20. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
    Ikezoe T, Ando K, Onozawa M, Yamane T, Hosono N, Morita Y, Kiguchi T, Iwasaki H, Miyamoto T, Matsubara K, Sugimoto S, Miyazaki Y, Kizaki M, Akashi K.
    Cancer Sci. 2022 Dec;113(12):4258-4266.
  21. Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes.
    Harada S, Onozawa M, Hidaka D, Yokoyama S, Senjo H, Takahashi S, Ogasawara R, Kanaya M, Mori A, Ota S, Kondo T, Teshima T.
    Ann Hematol. 2022 Jun;101(6):1239-1250.
  22. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ.
    Blood. 2022 Jun 9;139(23):3366-3375.
  23. [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
    Harada S, Okada K, Yokoyama S, Hidaka D, Hayase E, Onozawa M, Goto H, Hashimoto D, Kahata K, Endo T, Teshima T.
    Rinsho Ketsueki. 2021;62(11):1609-1614.
  24. Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
    Mori A, Onozawa M, Hidaka D, Yokoyama S, Miyajima T, Yokoyama E, Ogasawara R, Izumiyama K, Saito M, Fujisawa S, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Iwasaki H, Kobayashi H, Haseyama Y, Kurosawa M, Morioka M, Teshima T, Kondo T.
    Int J Hematol. 2022 Feb;115(2):188-197.
  25. Aleukemic Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia with E1A3 BCR-ABL1 Fusion Transcript.
    Miyashita N, Onozawa M, Suto K, Fujisawa S, Okazaki N, Hidaka D, Ohigashi H, Yasumoto A, Sugita J, Hashimoto D, Matsuno Y, Teshima T.
    Intern Med. 2022 Apr 1;61(7):1049-1054.
  26. Association of unbalanced translocation der(1;7) with germline GATA2 mutations.
    Kozyra EJ, Göhring G, Hickstein DD, Calvo KR, DiNardo CD, Dworzak M, de Haas V, Starý J, Hasle H, Shimamura A, Fleming MD, Inaba H, Lewis S, Hsu AP, Holland SM, Arnold DE, Mecucci C, Keel SB, Bertuch AA, Tawana K, Barzilai S, Hirabayashi S, Onozawa M, Lei S, Alaiz H, Andrikovics H, Betts D, Beverloo BH, Buechner J, Čermák M, Cervera J, Haus O, Jahnukainen K, Manola KN, Nebral K, Pasquali F, Tchinda J, Turkiewicz D, Van Roy N, Zemanova Z, Pastor VB, Strahm B, Noellke P, Niemeyer CM, Schlegelberger B, Yoshimi A, Wlodarski MW.
    Blood. 2021 Dec 9;138(23):2441-2445.
  27. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
    Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T.
    Int J Clin Oncol. 2021 Nov;26(11):2131-2141.
  28. Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL.
    Goldberg L, Negi V, Chung YJ, Onozawa M, Zhu YJ, Walker RL, Pierce R, Patel DP, Krausz KW, Gonzalez FJ, Goodell MA, Rodriguez BAT, Meltzer PS, Aplan PD.
    Cancer Res. 2021 Oct 1;81(19):5033-5046.
  29. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib.
    Kondo T, Onozawa M, Fujisawa S, Harada S, Ogasawara R, Izumiyama K, Saito M, Morioka M, Mori A, Teshima T.
    Hematology. 2021 Dec;26(1):256-260.
  30. A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia.
    Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T.
    Sci Rep. 2020 Nov 10;10(1):19400.
  31. Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody.
    de Leon MRP, Takahashi S, Onozawa M, Ito M, Nakano M, Senjo H, Chiba M, Ohigashi H, Yokoyama E, Sugita J, Hashimoto D, Teshima T.
    Blood Cell Ther. 2020 Aug 31;3(4):74-77.
  32. Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process.
    Hidaka D, Onozawa M, Miyashita N, Yokoyama S, Nakagawa M, Hashimoto D, Teshima T.
    Leuk Lymphoma. 2020 Nov;61(11):2722-2732.
  33. Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets.
    Miyashita N, Onozawa M, Yokoyama S, Hidaka D, Hayasaka K, Kunishima S, Teshima T.
    Hemasphere. 2019 Aug 7;3(4):e268.
  34. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.
    Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, Cieri N, Noviello M, Manfredi F, Montaldo E, Ostuni R, Naldini MM, Gentner B, Waterhouse M, Zeiser R, Finke J, Hanoun M, Beelen DW, Gojo I, Luznik L, Onozawa M, Teshima T, Devillier R, Blaise D, Halkes CJM, Griffioen M, Carrabba MG, Bernardi M, Peccatori J, Barlassina C, Stupka E, Lazarevic D, Tonon G, Rambaldi A, Cittaro D, Bonini C, Fleischhauer K, Ciceri F, Vago L.
    Nat Med. 2019 Apr;25(4):603-611.
  35. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
    Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C.
    Nat Commun. 2019 Mar 25;10(1):1065.
  36. Quantitative detection of IKZF1 deletion by digital PCR in patients with acute lymphoblastic leukemia.
    Hashiguchi J, Onozawa M, Okada K, Amano T, Hatanaka KC, Nishihara H, Sato N, Teshima T.
    Int J Lab Hematol. 2019 Apr;41(2):e38-e40.
  37. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D, Onozawa M, Hashiguchi J, Miyashita N, Kasahara K, Fujisawa S, Hayase E, Okada K, Shiratori S, Goto H, Sugita J, Nakagawa M, Hashimoto D, Kahata K, Endo T, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Imai K, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Shimizu C, Kondo T, Teshima T.
    Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e469-e479.
  38. Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia.
    Hashiguchi J, Onozawa M, Oguri S, Fujisawa S, Tsuji M, Okada K, Nakagawa M, Hashimoto D, Kahata K, Kondo T, Shimizu C, Teshima T.
    J Mol Diagn. 2018 Jul;20(4):446-454.
  39. Re-infection of Toxoplasma gondii after HSCT presenting lymphadenopathy resembling recurrence of lymphoma.
    Hashiguchi J, Onozawa M, Naka T, Hatanaka KC, Shiratori S, Sugita J, Fujimoto K, Matsuno Y, Teshima T.
    Transpl Infect Dis. 2018 Jun;20(3):e12892.
  40. A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction.
    Miyashita N, Onozawa M, Hayasaka K, Yamada T, Migita O, Hata K, Okada K, Goto H, Nakagawa M, Hashimoto D, Kahata K, Kondo T, Kunishima S, Teshima T.
    Ann Hematol. 2018 Apr;97(4):629-640.
  41. Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.
    Goldberg L, Gough SM, Lee F, Dang C, Walker RL, Zhu YJ, Bilke S, Pineda M, Onozawa M, Jo Chung Y, Meltzer PS, Aplan PD.
    Genes Chromosomes Cancer. 2017 Jun;56(6):472-483.
  42. Templated Sequence Insertion Polymorphisms in the Human Genome.
    Onozawa M, Aplan PD.
    Front Chem. 2016 Nov 16;4:43.
  43. Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy.
    Kasahara K, Onozawa M, Miyashita N, Yokohata E, Yoshida M, Kanaya M, Kosugi-Kanaya M, Takemura R, Takahashi S, Sugita J, Shigematsu A, Takahata M, Fujisawa S, Hashimoto D, Fujimoto K, Endo T, Kondo T, Teshima T.
    Case Rep Hematol. 2016;2016:2373902.
  44. [Ara-C].
    Onozawa M, Teshima T.
    Nihon Rinsho. 2015 Feb;73 Suppl 2:623-7.
  45. Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL.
    Cui Y, Onozawa M, Garber HR, Samsel L, Wang Z, McCoy JP, Burkett S, Wu X, Aplan PD, Mackall CL.
    Blood. 2015 May 7;125(19):2958-67.
  46. Landscape of insertion polymorphisms in the human genome.
    Onozawa M, Goldberg L, Aplan PD.
    Genome Biol Evol. 2015 Mar 4;7(4):960-8.
  47. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.
    Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, Rossi DJ, Ito K, Ge K, Aplan PD, Armstrong SA, Nussenzweig A.
    Nature. 2014 Oct 2;514(7520):107-11.
  48. Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome.
    Onozawa M, Zhang Z, Kim YJ, Goldberg L, Varga T, Bergsagel PL, Kuehl WM, Aplan PD.
    Proc Natl Acad Sci U S A. 2014 May 27;111(21):7729-34.
  49. NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function.
    Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD.
    Cancer Discov. 2014 May;4(5):564-77.